Garo Armen - Agenus Chairman
| AGEN Stock | USD 2.86 0.19 7.12% |
Chairman
Dr. Garo H. Armen, Ph.D., is the founder, Chairman of the Board and Chief Executive Officer of Agenus Inc. Dr. Armen is Chairman and Chief Executive Officer of Agenus Inc., which he cofounded in 1994. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. From mid2002 through 2004, he was Chairman of the Board of Directors for the biopharmaceutical company Elan Corporationrationration, plc which he helped restructure. Dr. Armen currently serves as nonexecutive Chairman of the Board of Directors of Protagenic Therapeutics, Inc., a publicly held biotechnology company since 1994.
| Age | 71 |
| Tenure | 30 years |
| Professional Marks | Ph.D |
| Address | 3 Forbes Road, Lexington, MA, United States, 02421-7305 |
| Phone | 781 674 4400 |
| Web | https://www.agenusbio.com |
Garo Armen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Garo Armen against Agenus stock is an integral part of due diligence when investing in Agenus. Garo Armen insider activity provides valuable insight into whether Agenus is net buyers or sellers over its current business cycle. Note, Agenus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Agenus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Garo Armen over a week ago Acquisition by Garo Armen of 1502 shares of Agenus at 10.86 subject to Rule 16b-3 | ||
Garo Armen over three months ago Acquisition by Garo Armen of 1055 shares of Agenus at 15.46 subject to Rule 16b-3 | ||
Garo Armen over three months ago Acquisition by Garo Armen of 65651 shares of Agenus at 11.9 subject to Rule 16b-3 | ||
Garo Armen over three months ago Acquisition by Garo Armen of 1040 shares of Agenus at 15.69 subject to Rule 16b-3 |
Agenus Management Efficiency
The company has return on total asset (ROA) of (0.2195) % which means that it has lost $0.2195 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7883) %, meaning that it created substantial loss on money invested by shareholders. Agenus' management efficiency ratios could be used to measure how well Agenus manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Equity is likely to grow to 1.61, while Return On Tangible Assets are likely to drop (0.91). At this time, Agenus' Asset Turnover is very stable compared to the past year.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Michael Forer | ADC Therapeutics SA | 55 | |
| MD FACP | Edgewise Therapeutics | 64 | |
| Ron Squarer | ADC Therapeutics SA | 54 | |
Management Performance
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.22 |
Agenus Inc Leadership Team
Elected by the shareholders, the Agenus' board of directors comprises two types of representatives: Agenus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agenus. The board's role is to monitor Agenus' management team and ensure that shareholders' interests are well served. Agenus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agenus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie DeSander, Chief Officer | ||
| Alfred Dadson, Chief Officer | ||
| Eric Humes, Chief Officer | ||
| Regina Grebla, VP Communications | ||
| Dr MBA, Chief Officer | ||
| John Castle, Head Bioinformatics | ||
| Zack Armen, Head Relations | ||
| Dhan Chand, Scientific Discovery | ||
| Christine Klaskin, Principal Accounting Officer and VP of Fin. | ||
| Jennifer Buell, Pres Therapeutics | ||
| Nils MD, Chief Officer | ||
| Tracy Clemente, Chief Officer | ||
| Garo Armen, Founder, Executive Chairman, CEO and Chairman of Bus. and Devel. Advisory Committee | ||
| Todd MD, Member Advisor | ||
| Craig Winter, Chief Officer | ||
| Robin JD, Chief Officer | ||
| Stephanie Fagan, Chief Officer |
Agenus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agenus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (1.42) % | ||||
| Operating Margin | (1.33) % | ||||
| Current Valuation | 96.24 M | ||||
| Shares Outstanding | 23.46 M | ||||
| Shares Owned By Insiders | 1.22 % | ||||
| Shares Owned By Institutions | 37.14 % | ||||
| Number Of Shares Shorted | 2.8 M | ||||
| Price To Earning | 10.52 X |
Pair Trading with Agenus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agenus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agenus will appreciate offsetting losses from the drop in the long position's value.Moving together with Agenus Stock
| 0.86 | ME | 23Andme Holding | PairCorr |
| 0.74 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.84 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Agenus Stock
| 0.57 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.54 | KZR | Kezar Life Sciences | PairCorr |
| 0.36 | MLYS | Mineralys Therapeutics, Downward Rally | PairCorr |
| 0.33 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Agenus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agenus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agenus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agenus Inc to buy it.
The correlation of Agenus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agenus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agenus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agenus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.02) | Revenue Per Share 7.808 | Quarterly Revenue Growth 0.033 | Return On Assets (0.22) | Return On Equity (12.79) |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.